Krystal Biotech (KRYS) Operating Leases: 2021-2025
Historic Operating Leases for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $9.5 million.
- Krystal Biotech's Operating Leases rose 27.22% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 27.22%. This contributed to the annual value of $6.0 million for FY2024, which is 8.70% down from last year.
- Per Krystal Biotech's latest filing, its Operating Leases stood at $9.5 million for Q3 2025, which was down 1.76% from $9.7 million recorded in Q2 2025.
- Krystal Biotech's 5-year Operating Leases high stood at $9.7 million for Q2 2025, and its period low was $3.9 million during Q1 2021.
- In the last 3 years, Krystal Biotech's Operating Leases had a median value of $8.3 million in 2023 and averaged $8.2 million.
- Per our database at Business Quant, Krystal Biotech's Operating Leases spiked by 140.16% in 2022 and then decreased by 25.89% in 2023.
- Krystal Biotech's Operating Leases (Quarterly) stood at $8.0 million in 2021, then increased by 11.33% to $8.9 million in 2022, then declined by 25.89% to $6.6 million in 2023, then dropped by 8.70% to $6.0 million in 2024, then increased by 27.22% to $9.5 million in 2025.
- Its Operating Leases was $9.5 million in Q3 2025, compared to $9.7 million in Q2 2025 and $9.7 million in Q1 2025.